
Kiniksa Pharmaceuticals, Ltd. KNSA
$ 45.3
1.82%
Annual report 2025
added 02-24-2026
Country |
|
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
74.2 M |
Market Cap[1] |
$ 3.36 B |
EBITDA (LTM) |
$ 24.2 M |
P/E (LTM) |
367.92 |
P/S (LTM) |
6.36 |
EPS (LTM) |
0.12 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Alector
ALEC
|
$ 2.19 | -9.77 % | $ 226 M | Nasdaq Global Select Market,SPB | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Cabaletta Bio
CABA
|
$ 3.34 | 0.45 % | $ 3.9 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Codexis
CDXS
|
$ 1.02 | 1.49 % | $ 74.9 M | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 3.74 | 3.6 % | $ 1.12 B | Nasdaq Global Select Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Cerus Corporation
CERS
|
$ 2.6 | 1.37 % | $ 480 M | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Cellectis S.A.
CLLS
|
$ 3.87 | -0.39 % | $ 116 M | Nasdaq Global Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 3.23 | 2.22 % | $ 1.23 M | Nasdaq Capital Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Collegium Pharmaceutical
COLL
|
$ 41.75 | 0.19 % | $ 1.32 B | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 36.14 | 1.23 % | $ 3.75 B | Nasdaq Capital Market,SPB | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Amarin Corporation plc
AMRN
|
$ 13.98 | 1.27 % | $ 5.7 B | Nasdaq Global Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Catalyst Pharmaceuticals
CPRX
|
$ 23.77 | 2.99 % | $ 2.91 B | Nasdaq Capital Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.41 | -1.87 % | $ 36.4 M | Nasdaq Global Market | ||
|
Cardiff Oncology
CRDF
|
$ 1.94 | 0.01 % | $ 130 M | Nasdaq Capital Market | ||
|
Curis
CRIS
|
$ 1.1 | -3.51 % | $ 6.94 M | Nasdaq Global Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
CorMedix
CRMD
|
$ 7.16 | 0.42 % | $ 364 M | Nasdaq Global Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Champions Oncology
CSBR
|
$ 6.14 | 3.89 % | $ 83.9 M | Nasdaq Capital Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.72 | -2.34 % | $ 4.84 M | Nasdaq Capital Market | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | ||
|
Altimmune
ALT
|
$ 4.21 | -2.32 % | $ 299 M | Nasdaq Global Market | ||
|
CEL-SCI Corporation
CVM
|
$ 3.88 | -8.92 % | $ 247 M | NYSE American,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.